
Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension...
HypertensionThe aim of present study is to evaluate the efficacy and safety of Carvedilol SR versus Carvedilol IR in Patients With Essential Hypertension

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
HypertensionThe purpose of the study is to evaluate the efficacy and safety of the study drug relative to an active comparator losartan which is in the same class of drug and is approved for use in the pediatric population aged 6 years and older. Approximately 260 subjects will participate in a 6-week, double-blind, randomized, treatment phase, followed by a 2-week, double-blind, randomized, placebo-controlled withdrawal phase. A 44-week, open-label extension in which all subjects will receive azilsartan and other antihypertensive medications (if needed). Blood pressure will be assessed throughout the study.

Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients
HypertensionCardiovascular RiskAlthough statins reduce cardiac events in hypertensive patients with cardiovascular risk factors, the effect of statins on coronary flow reserve (CFR) has not been examined in such patients. The investigators hypothesize that pitavastatin added to standard antihypertensive therapy will be superior to placebo in improving CFR in hypertensive patients with cardiovascular risk, and try to examine this hypothesis in a double-blind, randomized comparison study using Doppler echocardiography.

Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
HypertensionThe purpose of this study is to evaluate of efficacy and safety of cilinidipine plus valsartan and valsartan alone in patients with essential hypertension inadequately controlled on valsartan monotherapy

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle...
GlaucomaOcular Hypertension1 moreThe objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.

Faith-based Approaches in the Treatment of Hypertension (FAITH)
HypertensionThe purpose of this study is to test the effect of a church-based lifestyle intervention on blood pressure reduction in 400 hypertensive blacks (BP> 140/90 mm hg).

The Influence of Red Grape Cells on Blood Pressure Vascular Function in People With Hypertension...
HypertensionThe study hypothesis is that 3 Months Daily Supplementation of RGC will effect blood pressure and vascular function. This will be a single-center, double-blind, random, parallel controlled Study. Study population will include 60 subjects, who will be divided randomly into three groups. The first group will get RGC 200mg, the second group will get RGC 400mg, and the third group will get 200mg placebo.

Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure
HypertensionComparison of the combination of amlodipine with an angiotensin receptor blocker or an angiotensin converting inhibitor, on central arterial blood pressure in patients with hypertension and additional risk factors. This is a randomised, double-blind, double-dummy, multicenter study. The duration of active treatment 24 weeks.

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With...
GlaucomaOcular HypertensionThis study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled...
Type 2 DiabetesThe purpose of this study is to learn whether dapagliflozin, after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. The safety of this treatment will also be studied.